Product Dossier
APO-OLMESARTAN/AMLODIPINE
Product Dossier for APO-OLMESARTAN/AMLODIPINE (amlodipine, olmesartan medoxomil, Arrotex Pharmaceuticals). ARTG record, PBS listing, PBAC outcomes —…
- Sponsor: Arrotex Pharmaceuticals
- Active ingredient: amlodipine, olmesartan medoxomil
- Therapeutic area: Cardiology
- Related brand: NORVASC
- Related brand: CADIVAST
- Related brand: SEVIKAR
- Same area: ATOZET
- Same area: OPSUMIT
What it is
APO-OLMESARTAN/AMLODIPINE is a fixed-dose combination tablet containing olmesartan medoxomil and amlodipine (as besilate). The medicine is available in four strengths: 20/5 mg, 20/10 mg, 40/5 mg, and 40/10 mg, where the first number represents olmesartan medoxomil dose and the second represents amlodipine dose.
Regulatory history
APO-OLMESARTAN/AMLODIPINE was first listed on the ARTG on 13 June 2018.